New Delhi, Sept. 17 -- Indian pharmaceutical firms are making early preparations for the upcoming expiry of patents onNovo Nordisk's weight-loss drugsWegovyandOzempic-both based on the active ingredientSemaglutide.

When these patents lapse in 2026 in key markets such asBrazil,Canada,India, andChina, it opens up a potentially huge opportunity for generic drug makers.

Major Indian players likeDr. Reddy's LaboratoriesandMacleods Pharmaceuticalsare positioning themselves to supply the active pharmaceutical ingredients (APIs) required to manufacture generic versions.

APIs are the essential building blocks used to create final drug formulations for patients. Dr. Reddy's has already invested in a facility capable of producing 550 kilograms of...